MEK inhibition synergizes with TYK2 inhibitors in NF1-associated Malignant Peripheral Nerve Sheath Tumors.

Dana C Borcherding Neha V Amin Kevin He Xiaochun Zhang Yang Lyu Carina A Dehner Himanshi Bhatia Angad Gothra Layla Daud Peter Ruminski Christine A Pratilas Kai Pollard R Taylor Sundby Brigitte C Widemann Angela C Hirbe

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

These data provide the preclinical rationale for the development of a phase 1 clinical trial of deucravacitinib and mirdametinib in NF1-assosciated MPNST.

Keyphrases

peripheral nerve
clinical trial
pi k akt
signaling pathway
lps induced
nuclear factor
oxidative stress
electronic health record
inflammatory response
phase ii
big data
cell proliferation
open label
double blind
stem cells
cell therapy
phase iii
machine learning
toll like receptor